Genome BC : Regional Perspectiveson Personalized Medicinein British Columbia, CanadaEuroBioForum 2013 / MunichMay 28, 2013
• A catalyst for the life sciences cluster on Canadas West Coast• Cumulative portfolio of over $625M across 180 genomicsre...
Background• Co-founded by the late Dr. Michael Smith, NobelNobel Laureate, Genome British Columbiawas formed in July 2000....
Investment SourcesInternational,Industry &Institutional30%Provincial 25%Federal45%Research InvestmentObjectives• Match BC’...
Research Funding ContinuumDiscovery Research Applied TranslationalGenome BC invests in critical space along the researchfu...
Discovery large scale Genome BCGenome BC & GenomeCanada2002 2004 2005 2006 2007 2008 2009 2010 2011 20122003 2013 20142001...
Personalized Medicine : a New Paradigm“One-size-fits-all” paradigm:Same frequency of testing for large population (e.g.mam...
British Columbia Health Care Context• A population of 4.6 million• Publically funded, single payer system• delivery via re...
Support for Personalized Medicine in British ColumbiaPersonalized Medicine Program (PMP) (Genome BC)• investigator-driven ...
Genomics Applied to the Management of High-riskAML/Myelodysplastic syndromes – Karsan and Marra ($3.0M)(BC Cancer Agency, ...
Clinical Implementation of Diagnostic Biomarker Assays in Heartand Kidney Transplantation – McManus et al ($2.0M)(St. Paul...
Genomics and Personalized Health – New Projects12Project Leader(s) Project TitleTotalbudgetJoseph ConnorsMarco MarraRandy ...
The realityThe hope50% 50% 80% 20%• We are still doing research• The transition to development not easy• The shift to impa...
Lessons Learned• Success in translation varies by disease area• Difficulty achieving milestones (e.g. ending research anda...
WHAT CAN WE OFFER?• Publicly funded, single payer system• Single medical school with strong ties to many communities andhe...
WHAT ARE WE LOOKING FOR?• International partnership and collaboration• People we can work with• Groups that can articulate...
• Cohorts• Biostatistics / Bioinformatics• End-user buy-inTOP 3 recommendationsfor achieving tangible results17
For More Information:Website:www.genomebc.caContact:THANK YOU!Rachael Ritchie, Director of Business Developmentrritchie@ge...
Upcoming SlideShare
Loading in …5
×

EuroBioForum 2013 - Day 2 | Rachael Ritchie

365
-1

Published on

EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013

=======================================

# REGIONAL PERSPECTIVES #

Genome British Colombia, Canada:
Regional Perspectives on Personalized Medicine in British Columbia, Canada

Dr Rachael Ritchie
Director Business Development Genome British Colombia

=======================================

http://www.eurobioforum.eu

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
365
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

EuroBioForum 2013 - Day 2 | Rachael Ritchie

  1. 1. Genome BC : Regional Perspectiveson Personalized Medicinein British Columbia, CanadaEuroBioForum 2013 / MunichMay 28, 2013
  2. 2. • A catalyst for the life sciences cluster on Canadas West Coast• Cumulative portfolio of over $625M across 180 genomicsresearch projects and science and technology platforms• Focusing on sectors of economic importance to BC andCanada:• Agriculture• Aquaculture & Fisheries• Forestry• Mining, Energy & Environment• Human Health• To generate social and economic benefitsGenome British Columbia2
  3. 3. Background• Co-founded by the late Dr. Michael Smith, NobelNobel Laureate, Genome British Columbiawas formed in July 2000.• The initial strategic plan covered the period 2001through 2005, with a $69M program.• Genome BC has successfully implemented its secondstrategic plan (2005-2010) and exceeded the $300Mresearch program.• Genome BC has initiated its third strategic plan (2010-2015)and plans a $340M research program. 3
  4. 4. Investment SourcesInternational,Industry &Institutional30%Provincial 25%Federal45%Research InvestmentObjectives• Match BC’s key economicconcerns.• Leverage contributions fromother organizations.• Maintain partnerships with abroad cross-section ofprovincial institutions, andlocations.4
  5. 5. Research Funding ContinuumDiscovery Research Applied TranslationalGenome BC invests in critical space along the researchfunding continuum to bring genomics discoveries fromthe bench into real world applications5Commercialization
  6. 6. Discovery large scale Genome BCGenome BC & GenomeCanada2002 2004 2005 2006 2007 2008 2009 2010 2011 20122003 2013 20142001Translation – securing benefitsApplicationThe Evolution of Genome BC programs
  7. 7. Personalized Medicine : a New Paradigm“One-size-fits-all” paradigm:Same frequency of testing for large population (e.g.mammograms)Symptom-drivendiagnosisTherapy based onclinical symptomsMonitoring basedon clinicalsymptomsPersonalized medicine paradigm:Test for markersthat risk (e.g.genetic variants incancer)Focusedprevention effortsin people withriskFocusedmonitoring inpeople withriskMolecularmonitoring fordisease subtypesTargeted therapybased on diseasesubtype, risk ofadverse responseMolecularmonitoring forresponse totherapySource: Personalized Medicine Coalition7
  8. 8. British Columbia Health Care Context• A population of 4.6 million• Publically funded, single payer system• delivery via regional & provincial authorities• $15.51 billion health-care budget (+5.8%/yr2)• $3,360 / per capita• $180M in research spending (2011/12) 3• BC Cancer Agency (BCCA)• Michael Smith Genome Sciences Centre (GSC)• BC Center for Disease Control (BCCDC)• Center for Drug Research and Discovery (CDRD)1 2012 year 2For the period 2000-2010.3 www.phsa.ca/research report (2012)
  9. 9. Support for Personalized Medicine in British ColumbiaPersonalized Medicine Program (PMP) (Genome BC)• investigator-driven larger-scale projects in human health• outcomes are ready for clinic use and/or uptake into the health systemwithin 3 years of launch• Must demonstrate the support from the payer (e.g. a regional healthauthority) & the potential cost-effectiveness of the translation of theproposed research to the healthcare system• project budget up to $3 million• similar to the Wellcome Trust “Health Innovation Challenge Fund”Genomics and Personalized Health (GPH) (Genome Canada)• in partnership with Canadian Institutes of Health Research (CIHR),• outcomes concrete deliverables clinical utility and/or practical applicability• project budget $10 million 9
  10. 10. Genomics Applied to the Management of High-riskAML/Myelodysplastic syndromes – Karsan and Marra ($3.0M)(BC Cancer Agency, BC Cancer Foundation; $3.0M)Primary Research Objective• Develop a genome-wide sequencing assay of RNA and/or DNA on a next-generationsequencing platform and ensure that all the known mutations that predict outcomeof AML treatment are identified in a cost-effective mannerImplementation of a Pharmacogenetic ADR Prevention Programin BC – Hayden and Carleton ($4.0M)(Children’s and Women’s Health Centre and UBC; co-funding partners include Merck,IBM, Pfizer; builds on earlier $12.4M investment in two projects)Primary Research Objective• Demonstrate the utility and cost-effectiveness of pharmacogenetic tests designed toprevent cisplatin-induced deafness and anthracycline-induced heart failure10
  11. 11. Clinical Implementation of Diagnostic Biomarker Assays in Heartand Kidney Transplantation – McManus et al ($2.0M)(St. Paul’s Hospital, Vancouver Coastal Heath, and UBC; builds on earlier $15.6M investmentin two projects)Primary Research Objective• To develop simple, safe, accurate, and cost-effective diagnostic tools that improvetransplant patient outcomes and reduce costsStratifying and Targeting Pediatric Medulloblastoma ThroughGenomics - Marra ($9.9M)(Hospital for Sick Children, Genome Canada, Terry Fox Research Institute, OntarioInstitute for Cancer Research et al.)Primary Research Objective• To develop markers that will more accurately classify the medulloblastomas, themost common form of childhood brain cancer, to optimize treatments to improvethe quality of life of patients. 11
  12. 12. Genomics and Personalized Health – New Projects12Project Leader(s) Project TitleTotalbudgetJoseph ConnorsMarco MarraRandy GascoynePersonalized Treatment of Lymphoid Cancer: British Columbia as Model Province $10MRichard HarriganJulio MontanerViral and Human Genetic Predictors of Response to HIV Therapies $4.9MAndrew PennChristoph BorchersShelagh CouttsReducing Stroke Burden with Hospital-Ready Biomarker Test for Rapid TIA Triage $9.8MDon SinRaymond NgClinical Implemetation and Outcomes Evaluation of Blood-Based Biomarkers for COPDManagement$7.2M
  13. 13. The realityThe hope50% 50% 80% 20%• We are still doing research• The transition to development not easy• The shift to impact even more difficultresearch researchdevelopment developmentR & D in Personalized Medicine13
  14. 14. Lessons Learned• Success in translation varies by disease area• Difficulty achieving milestones (e.g. ending research andachieving clinical validation)• Insufficient data provided to demonstrate achievement ofmilestones• Stratification reduces effective population sample sizes,making replication difficult• The pathway to translation envisioned may not be realistic• Existing or emerging competition may limit potential fortranslational success—need to figure out win-win-win14
  15. 15. WHAT CAN WE OFFER?• Publicly funded, single payer system• Single medical school with strong ties to many communities andhealthcare organizations• Critical mass of researchers, physicians and healthcare providers• A networked, centralized system of care in key disease areas(e.g., cancer, transplantation, pediatric ailments, cardiac, renaland infectious diseases)• Strong track record in supporting excellence in health research• ongoing projects, funded projects• Innovative organizations• Genome Canada Science and Technology Innovation Centres (Proteomics,Metabolomics & Michael Smith Genome Sciences Centre)• BCCA – BC Cancer Agency• BCCDC – BC Centre for Disease Control• CDRD –Center for Drug Research and Discovery 15
  16. 16. WHAT ARE WE LOOKING FOR?• International partnership and collaboration• People we can work with• Groups that can articulate what they need so we canget a win-win16
  17. 17. • Cohorts• Biostatistics / Bioinformatics• End-user buy-inTOP 3 recommendationsfor achieving tangible results17
  18. 18. For More Information:Website:www.genomebc.caContact:THANK YOU!Rachael Ritchie, Director of Business Developmentrritchie@genomebc.ca18
  1. A particular slide catching your eye?

    Clipping is a handy way to collect important slides you want to go back to later.

×